In July 2012, USA Today reported that Opana ER had become the drug of choice for people seeking narcotics, and that in Nassau County, hundreds of people each month were seeking treatment for addiction to Opana ER.Īs a result of concerns regarding the role of Opana ER in the larger opioid abuse epidemic and Endo’s marketing practices, the Office of the Attorney General launched an investigation of Endo, focusing on Opana ER. In May 2011, after a spike in opioid prescribing and abuse, Nassau County issued a Public Health Alert on the increasing abuse of Opana ER, warning the public and law enforcement of the dangers of associated with the drug. Endo’s opioid drug Opana ER has been widely abused in New York State. headquarters in Pennsylvania, makes a variety of prescription drugs. According to the federal Centers for Disease Control and Prevention, in New York State, from 2003 to 2012, deaths involving opioid analgesics increased five-fold, from 179 in 2003 to 883 in 2012.Įndo, an Irish company with U.S. The resulting increase in the prescribing of opioids is associated with a sharp increase in the prevalence of opioid addiction, which in turn has been associated with a rise in overdose deaths and heroin use. According to the New York City Department of Health and Mental Hygiene, between 20, the number of opioid painkiller prescriptions filled by New York City residents increased by 31%, from approximately 1.6 million to approximately 2.2 million. The use of prescription opioids to manage chronic non-cancer pain has increased ten-fold over the past 20 years in the United States, with a concomitant increase in opioid-related health problems. “My office is committed to ensuring that prescription drugs are marketed and prescribed responsibly – and that consumers get the information they need about the serious risks associated with painkillers, such as addiction.” “The public health crisis created by improper opioid prescribing in New York remains pervasive and extremely dangerous,” said Attorney General Schneiderman. Endo must also create a program that will prevent its sales staff from promoting this powerful narcotic painkiller to health care providers who may be involved in the abuse and illegal diversion of opioids. The agreement requires Endo to cease all misrepresentations regarding the properties of Opana ER, to describe accurately the risk of addiction to Opana ER, and to summarize studies regarding Opana ER on its website. (“Endo”), which make and sell the long-acting opioid, Opana ER. Schneiderman today announced an agreement with Endo Health Solutions Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |